Propanc Biopharma, Inc. (PPCB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 948.27 Thousand USD | 73.7% |
| 2023 | 545.91 Thousand USD | -50.3% |
| 2022 | 1.09 Million USD | 61.5% |
| 2021 | 680.08 Thousand USD | -58.37% |
| 2020 | 1.63 Million USD | -4.41% |
| 2019 | 1.7 Million USD | -64.05% |
| 2018 | 4.75 Million USD | 36.53% |
| 2017 | 3.48 Million USD | 189.04% |
| 2016 | 1.2 Million USD | -33.88% |
| 2015 | 1.82 Million USD | 289.05% |
| 2014 | 468.3 Thousand USD | 1324.12% |
| 2013 | 32.88 Thousand USD | -56.15% |
| 2012 | 75 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 693.96 Thousand USD | 27.12% |
| 2024 Q3 | 800.25 Thousand USD | -21.38% |
| 2024 Q4 | 948.27 Thousand USD | 18.5% |
| 2024 Q2 | 1.01 Million USD | 46.68% |
| 2023 Q3 | 680.68 Thousand USD | -22.1% |
| 2023 Q1 | 1.01 Million USD | -7.58% |
| 2023 FY | 545.91 Thousand USD | -50.3% |
| 2023 Q2 | 873.76 Thousand USD | -13.92% |
| 2023 Q4 | 545.91 Thousand USD | -19.8% |
| 2022 Q1 | 637.99 Thousand USD | -6.19% |
| 2022 FY | 1.09 Million USD | 61.5% |
| 2022 Q4 | 1.09 Million USD | -2.9% |
| 2022 Q3 | 1.13 Million USD | 10.2% |
| 2022 Q2 | 1.02 Million USD | 60.89% |
| 2021 Q2 | 1.28 Million USD | 16.16% |
| 2021 Q1 | 1.1 Million USD | -32.51% |
| 2021 FY | 680.08 Thousand USD | -58.37% |
| 2021 Q4 | 680.08 Thousand USD | -32.96% |
| 2021 Q3 | 1.01 Million USD | -20.81% |
| 2020 Q1 | 2.63 Million USD | 54.35% |
| 2020 Q2 | 3.02 Million USD | 14.61% |
| 2020 Q3 | 2.78 Million USD | -7.94% |
| 2020 FY | 1.63 Million USD | -4.41% |
| 2020 Q4 | 1.63 Million USD | -41.31% |
| 2019 FY | 1.7 Million USD | -64.05% |
| 2019 Q3 | 2.12 Million USD | -25.62% |
| 2019 Q2 | 2.85 Million USD | -25.22% |
| 2019 Q1 | 3.81 Million USD | -19.81% |
| 2019 Q4 | 1.7 Million USD | -19.39% |
| 2018 FY | 4.75 Million USD | 36.53% |
| 2018 Q3 | 4.57 Million USD | 3.44% |
| 2018 Q2 | 4.41 Million USD | -5.07% |
| 2018 Q1 | 4.65 Million USD | 33.7% |
| 2018 Q4 | 4.75 Million USD | 3.99% |
| 2017 Q1 | 548.87 Thousand USD | -54.44% |
| 2017 Q2 | 1.82 Million USD | 232.74% |
| 2017 Q3 | 2.65 Million USD | 45.3% |
| 2017 Q4 | 3.48 Million USD | 31.22% |
| 2017 FY | 3.48 Million USD | 189.04% |
| 2016 Q1 | 2.15 Million USD | 18.29% |
| 2016 FY | 1.2 Million USD | -33.88% |
| 2016 Q4 | 1.2 Million USD | 20.31% |
| 2016 Q3 | 1 Million USD | -48.69% |
| 2016 Q2 | 1.95 Million USD | -9.44% |
| 2015 Q1 | 422.03 Thousand USD | -9.88% |
| 2015 FY | 1.82 Million USD | 289.05% |
| 2015 Q2 | 503.48 Thousand USD | 19.3% |
| 2015 Q4 | 1.82 Million USD | 56.27% |
| 2015 Q3 | 1.16 Million USD | 131.56% |
| 2014 Q1 | 24.21 Thousand USD | -26.37% |
| 2014 FY | 468.3 Thousand USD | 1324.12% |
| 2014 Q4 | 468.3 Thousand USD | 520.29% |
| 2014 Q3 | 75.49 Thousand USD | 74.39% |
| 2014 Q2 | 43.29 Thousand USD | 78.81% |
| 2013 Q4 | 32.88 Thousand USD | -12.54% |
| 2013 FY | 32.88 Thousand USD | -56.15% |
| 2013 Q3 | 37.59 Thousand USD | -1.22% |
| 2013 Q2 | 38.06 Thousand USD | 126.52% |
| 2013 Q1 | 16.8 Thousand USD | -77.6% |
| 2012 Q3 | 143.16 Thousand USD | 107.44% |
| 2012 Q4 | 75 Thousand USD | -47.61% |
| 2012 FY | 75 Thousand USD | 0.0% |
| 2012 Q2 | 69.01 Thousand USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 97.699% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 76.995% |
| SQZ Biotechnologies Company | 27.47 Million USD | 96.548% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 97.814% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 96.814% |
| Mesoblast Limited | 118.7 Million USD | 99.201% |
| Genus plc | 233.1 Million USD | 99.593% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 67.64% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 29.422% |
| Marizyme, Inc. | 18.71 Million USD | 94.934% |
| ContraFect Corporation | 2.88 Million USD | 67.085% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -26.436% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -599.898% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 34.436% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 59.231% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 83.241% |
| MultiCell Technologies, Inc. | 202.58 USD | -467997.048% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 98.351% |
| EV Biologics, Inc. | 1.49 Million USD | 36.56% |
| Q BioMed Inc. | 4.1 Million USD | 76.928% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 97.135% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -50.501% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 22.802% |
| Biomind Labs Inc. | 735.54 Thousand USD | -28.921% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.447% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 92.704% |
| Skye Bioscience, Inc. | 4.61 Million USD | 79.454% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -6.78% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -570.071% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 83.848% |
| IMV Inc. | 28.88 Million USD | 96.717% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -3587.045% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 58.011% |
| GB Sciences, Inc. | 1.75 Million USD | 46.1% |
| Alpha Cognition Inc. | 1.22 Million USD | 22.297% |
| HST Global, Inc. | 98.31 Thousand USD | -864.484% |
| CSL Limited | 12.18 Billion USD | 99.992% |
| Halberd Corporation | 150 Thousand USD | -532.181% |
| Enzolytics Inc. | 996.33 Thousand USD | 4.824% |
| Resverlogix Corp. | 6.49 Million USD | 85.391% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -98.591% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -271.01% |
| argenx SE | 20 Million USD | 95.259% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 97.919% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 64.992% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -9174.044% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.773% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -372.68% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 60.451% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -313.567% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 98.598% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 68.665% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -163.621% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 95.335% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -537.905% |
| BioStem Technologies, Inc. | 4.71 Million USD | 79.873% |
| ONE Bio Corp. | 19.71 Million USD | 95.19% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -279.032% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -281.26% |
| Agentix Corp. | 50 Thousand USD | -1796.542% |
| LadRx Corporation | 33.6 Thousand USD | -2721.731% |
| Cell Source, Inc. | 9.25 Million USD | 89.753% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -25.399% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -25.399% |
| NovAccess Global Inc. | 2.19 Million USD | 56.894% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 86.593% |
| Itoco Inc. | 228.37 Thousand USD | -315.222% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -349.471% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 80.97% |
| Kadimastem Ltd | 891.22 Thousand USD | -6.401% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -135.977% |
| CytoDyn Inc. | 30.07 Million USD | 96.847% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -95.809% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -169.512% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 87.874% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -674.099% |
| Rebus Holdings, Inc. | 310 Thousand USD | -205.894% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 79.974% |
| International Stem Cell Corporation | 4.17 Million USD | 77.303% |
| Bioxytran, Inc. | 1.92 Million USD | 50.739% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1419.349% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 56.519% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 88.597% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 88.954% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 39.037% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -253.832% |
| Neutra Corp. | 54.15 Thousand USD | -1650.999% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 48.182% |
| PureTech Health plc | 25.51 Million USD | 96.283% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 22.541% |
| IXICO plc | 472.02 Thousand USD | -100.895% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 93.883% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 98.477% |
| CSL Limited | 12.18 Billion USD | 99.992% |
| Cellectis S.A. | 92.77 Million USD | 98.978% |